Comparing the current results to its competitors, Cullinan Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 7.07 %, recorded in the same quarter.
Cullinan Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic research institutions, governmental agencies, and public and private research organizations worldwide. Competitors may possess greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing. Smaller or early-stage companies can also be significant competitors, particularly through collaborations with larger firms. Competition extends to recruiting and retaining qualified personnel, establishing clinical trial sites, recruiting patients, and acquiring complementary technologies. Regarding the CLN-978 program, the company is aware of multiple companies developing CD19 T cell engager programs for treatment.
October 16, 2024
Trailblazing in Autoimmune Therapies: Cullinan Therapeutics Garners FDA IND Clearance for CLN-978 in Lupus Treatment In a significant stride for autoimmune disease treatment, Cullinan Therapeutics Inc. recently received FDA clearance for its Investigational New Drug (IND) application to administer CLN-978 subcutaneously in patients with moderate to severe systemic lupus erythematosus (SLE). This pioneering decision marks CLN-978 as the first development-stage CD19 T cell engager to receive IND clearance from the U.S. FDA for autoimmune diseases, signifying a potential breakthrough in targeting debilitating immune disorders. Breaking New Ground with CLN-978 CLN-978 represents a novel approach by leveraging th...
September 16, 2024
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus In a noteworthy move for both the company and patients suffering from systemic lupus erythematosus (SLE), Cullinan Therapeutics has officially submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for their novel therapeutic candidate, CLN-978. This development could signify a substantial leap forward in the treatment options for this chronic autoimmune disease, which currently impacts many lives with its debilitating symptoms.Systemic lupus erythematosus is characterized by the immune system ...
June 1, 2024
Pioneering Progress: Cullinan Therapeutics Announces Promising Results from the Phase 2b REZILIENT1 Study of Zipalertinib in NSCLC with EGFR Exon 20 Insertion Mutations In the ever-evolving landscape of oncology research, achieving meaningful outcomes for patients with non-small cell lung cancer (NSCLC) remains an imperative. Cullinan Therapeutics has recently made significant strides in this arena, announcing promising initial data from their pivotal Phase 2b REZILIENT1 study. The investigational drug, zipalertinib, demonstrated an response rate (ORR) of 39% in patients with NSCLC harboring EGFR Exon 20 insertion mutations. These patients, notably, had progressed following prior treatment with amivantamab...
April 24, 2024
Cullinan Therapeutics, a biopharmaceutical company focused on modality-agnostic targeted therapies, is set to present clinical data from its Phase 1 trial of CLN-619 at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The conference will be held from May 31 to June 4, 2024, in Chicago.The study focuses on evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CLN-619, a novel anti-MICA/B antibody, both as monotherapy and in combination with the checkpoint inhibitor pembrolizumab. The initial results from the dose escalation cohort of CLN-619 in combination with pembrolizumab will be presented alongside updated results from the monothera...
March 1, 2024
Cullinan Oncology, a biopharmaceutical company focused on developing novel cancer treatments, recently announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for CLN-619, a promising antibody designed to target MICA/B in patients with relapsed or refractory multiple myeloma. This marks an important milestone for the company, as it paves the way for the initiation of a Phase 1 study for CLN-619, which will be the first clinical trial involving a MICA/B antibody in hematologic malignancies.Multiple myeloma is a type of blood cancer that arises from plasma cells, which are a type of white blood cell that produce antibodies. Wh...
Publicly Traded Peers of Cullinan Therapeutics Inc
Sanofi Share Performance
-9.45%
One Year
Sanofi
Profile
Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
Sources:
Cullinan Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cullinan Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
